Ching‐Wei Chang

2.3k total citations
64 papers, 1.5k citations indexed

About

Ching‐Wei Chang is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Ching‐Wei Chang has authored 64 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 24 papers in Pulmonary and Respiratory Medicine and 19 papers in Molecular Biology. Recurrent topics in Ching‐Wei Chang's work include Advanced Breast Cancer Therapies (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (6 papers). Ching‐Wei Chang is often cited by papers focused on Advanced Breast Cancer Therapies (13 papers), Cancer Immunotherapy and Biomarkers (12 papers) and Cancer Genomics and Diagnostics (6 papers). Ching‐Wei Chang collaborates with scholars based in United States, Taiwan and United Kingdom. Ching‐Wei Chang's co-authors include Nysia I. George, Luciana Molinero, Chuhsing Kate Hsiao, Por T. Hung, Yung‐Feng Shih, Chien‐Jen Chen, Luke Lin, John D. Powderly, Sylvia Adams and Sara M. Tolaney and has published in prestigious journals such as Nature Communications, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Ching‐Wei Chang

60 papers receiving 1.4k citations

Peers

Countries citing papers authored by Ching‐Wei Chang

Since Specialization

Citations

This map shows the geographic impact of Ching‐Wei Chang's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ching‐Wei Chang with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ching‐Wei Chang more than expected).

Fields of papers citing papers by Ching‐Wei Chang

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ching‐Wei Chang. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ching‐Wei Chang. The network helps show where Ching‐Wei Chang may publish in the future.

Co-authorship network of co-authors of Ching‐Wei Chang

This figure shows the co-authorship network connecting the top 25 collaborators of Ching‐Wei Chang. A scholar is included among the top collaborators of Ching‐Wei Chang based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ching‐Wei Chang. Ching‐Wei Chang is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	ERα dysfunction caused by ESR1 mutations and therapeutic pressure promotes lineage plasticity in ER+ breast cancer 2025 ·Nature Cancer ·(unknown), Xiaosai Yao, Patrick Aouad, (unknown), Lisa Crocker, Subhra Chaudhuri, Yuxin Liang, Spyros Darmanis, Jennifer M. Giltnane, Heather M. Moore, Junko Aimi, Ching‐Wei Chang, Mary Gates, Jennifer Eng‐Wong, Marc Hafner, Ciara Metcalfe	3
2	Abstract PS17-01: Key drivers of therapeutic response and resistance to giredestrant from GO39932: a Phase Ia/b study in patients with estrogen receptor-positive, HER2-negative, locally advanced or metastatic breast cancer 2024 ·Cancer Research ·Jackson J. Liang, Christy C. Ong, Jennifer M. Giltnane, Junko Aimi, Ching‐Wei Chang, Mary Gates, Jennifer Eng‐Wong, Pablo Ernesto Pérez, Komal Jhaveri, Elgene Lim, Nicholas C. Turner, Heather M. Moore	1
3	Structural and catalytic studies of Six-Membered amino N-Heterocyclic carbene palladium (II) complexes with a triazine backbone for Suzuki coupling reaction 2024 ·Inorganica Chimica Acta ·Ming‐Tsz Chen, Cheng‐Chun Huang, Ching‐Wei Chang, Kuan-Yu Liu	2
4	An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer 2023 ·Clinical Cancer Research ·Sarat Chandarlapaty, Maura N. Dickler, José Alejandro Pérez Fidalgo, Rafael Villanueva-Vázquez, Jennifer M. Giltnane, Mary Gates, Ching‐Wei Chang, Sravanthi Cheeti, Jill Fredrickson, Xiaojing Wang, (unknown), Heather M. Moore, Ciara Metcalfe, Jennifer Lauchle, Eric W. Humke, Aditya Bardia	7
5	71 Integration of RNA in situ hybridization and sequential immunofluorescence for same-slide fully automated multi-omics analysis of the tumor microenvironment 2023 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), Paula Juricic, Pino Bordignon, (unknown), (unknown), (unknown), (unknown), (unknown), Steve Zhou, Ching‐Wei Chang, Li-Chong Wang	1
6	Giredestrant reverses progesterone hypersensitivity driven by estrogen receptor mutations in breast cancer 2022 ·Science Translational Medicine ·(unknown), Ellen Ingalla, Xiaosai Yao, (unknown), (unknown), Jennifer M. Giltnane, Yuxin Liang, Anneleen Daemen, Heather M. Moore, Junko Aimi, Ching‐Wei Chang, Mary Gates, Jennifer Eng‐Wong, Lucinda Tam, (unknown), Merone Roose‐Girma, Meritxell Bellet, Marc Hafner, Ciara Metcalfe	9
7	The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer 2022 ·Breast Cancer Research and Treatment ·Aditya Bardia, Ingrid A. Mayer, Eric P. Winer, Hannah M. Linden, X. Cynthia, Barbara A. Parker, Meritxell Bellet, Carlos L. Arteaga, Sravanthi Cheeti, Mary Gates, Ching‐Wei Chang, Jill Fredrickson, Jill M. Spoerke, Heather M. Moore, Jennifer M. Giltnane, Lori S. Friedman, Edna Chow Maneval, Iris T. Chan, Komal Jhaveri	14
8	A Phase I Study of DLYE5953A, an Anti-LY6E Antibody Covalently Linked to Monomethyl Auristatin E, in Patients with Refractory Solid Tumors 2020 ·Clinical Cancer Research ·Sara M. Tolaney, T. Khanh, Joseph P. Eder, Patricia LoRusso, Colin D. Weekes, Sarat Chandarlapaty, Ching‐Wei Chang, (unknown), (unknown), (unknown), Flávia Brunstein, Montserrat Carrasco‐Triguero, Walter C. Darbonne, Jennifer M. Giltnane, W. Michael Flanagan, S. Renee Commerford, Alexander Ungewickell, Geoffrey I. Shapiro, Shanu Modi	15
9	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer 2020 ·Nature Communications ·Mélanie Desbois, Akshata R. Udyavar, Lisa Ryner, Cleopatra Kozlowski, Yinghui Guan, Milena Dürrbaum, Shan Lu, Jean‐Philippe Fortin, Hartmut Koeppen, James Ziai, Ching‐Wei Chang, Shilpa Keerthivasan, Marie Plante, Richard Bourgon, Carlos Bais, Priti S. Hegde, Anneleen Daemen, Shannon J. Turley, Yulei Wang	139
10	Low-pass Whole-genome Sequencing of Circulating Cell-free DNA Demonstrates Dynamic Changes in Genomic Copy Number in a Squamous Lung Cancer Clinical Cohort 2019 ·Clinical Cancer Research ·Xiaoji Chen, Ching‐Wei Chang, Jill M. Spoerke, (unknown), (unknown), (unknown), Junko Aimi, Mamie Yu, (unknown), (unknown), Ling‐Yuh Huw, Steven Gendreau, Craig Cummings, Mark R. Lackner	54
11	Genomic Alterations Associated with Recurrence and TNBC Subtype in High-Risk Early Breast Cancers 2018 ·Molecular Cancer Research ·Timothy R. Wilson, Akshata R. Udyavar, Ching‐Wei Chang, Jill M. Spoerke, Junko Aimi, Heidi Savage, Anneleen Daemen, Joyce O’Shaughnessy, Richard Bourgon, Mark R. Lackner	15
12	Transcript profiling in the testes and prostates of postnatal day 30 Sprague-Dawley rats exposed prenatally and lactationally to 2-hydroxy-4-methoxybenzophenone 2018 ·Reproductive Toxicology ·Noriko Nakamura, Vikrant Vijay, Varsha G. Desai, Deborah K. Hansen, Tao Han, Ching‐Wei Chang, Yu‐Chuan Chen, Wafa Harrouk, Barry Mcintyre, Paul M.D. Foster, James C. Fuscoe, Amy L. Inselman	5
13	Cost-sensitive performance metric for comparing multiple ordinal classifiers 2016 ·PubMed ·Nysia I. George, Tzu‐Pin Lu, Ching‐Wei Chang	7
14	Effects of a 28-day dietary co-exposure to melamine and cyanuric acid on the levels of serum microRNAs in male and female Fisher 344 rats 2016 ·Food and Chemical Toxicology ·(unknown), Ching‐Wei Chang, D.H. Williams, Patricia Porter‐Gill, Gonçalo Gamboa da Costa, Luísa Camacho	8
15	Evaluation of multiple mechanism-based toxicity endpoints in primary cultured human hepatocytes for the identification of drugs with clinical hepatotoxicity: Results from 152 marketed drugs with known liver injury profiles 2015 ·Chemico-Biological Interactions ·Jie Zhang, (unknown), Ayako Suzuki, Ching‐Wei Chang, Jürgen Borlak, Albert P. Li, Weida Tong	33
16	Metabolic fate of fructose in human adipocytes: a targeted 13C tracer fate association study 2014 ·Metabolomics ·Vijayalakshmi Varma, László G. Boros, Greg T. Nolen, Ching‐Wei Chang, Martin Wabitsch, Richard D. Beger, Jim Kaput	30
17	Gene Expression Variability in Human Hepatic Drug Metabolizing Enzymes and Transporters 2013 ·PLoS ONE ·Lun Yang, (unknown), Ching‐Wei Chang, Yan Li, Ying Huang, (unknown), Yongli Guo, Jim Kaput, Leming Shi, Baitang Ning	45
18	Spatially Fractionated Radiation Induces Cytotoxicity and Changes in Gene Expression in Bystander and Radiation Adjacent Murine Carcinoma Cells 2012 ·Radiation Research ·(unknown), Sunil Sharma, Ching‐Wei Chang, José Peñagarícano, (unknown), Eduardo G. Moros, Peter M. Corry, Robert J. Griffin	74
19	Evaluation of p53 genotype on gene expression in the testis, liver, and heart from male C57BL/6 mice 2011 ·Transgenic Research ·Dayton M. Petibone, Rohan Kulkarni, Ching‐Wei Chang, James J. Chen, Suzanne M. Morris	1
20	XPC is essential for nucleotide excision repair of zidovudine-induced DNA damage in human hepatoma cells 2010 ·Toxicology and Applied Pharmacology ·Qiangen Wu, Frederick A. Beland, Ching‐Wei Chang, Jia‐Long Fang	16

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact